Disclosure of material issue

SMS Lifesciences (soon to be Haleos Labs) has successfully cleared an audit by Brazil's health authority, ANVISA, for its API manufacturing facility (Unit-1). This regulatory win means their plant meets international quality standards, opening the door for the company to enter Brazil, South America's largest pharmaceutical market.

This move could significantly boost market access and future growth prospects for the company. 🇧🇷✅🚀